PTC Therapeutics stock analysis
PTC Therapeutics (P91) Stock Price & Analysis
P91 Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 4.28B
- Enterprise Value
- CHF 3.92B
- Total Cash (Recent Filing)
- CHF 2.13B
- Total Debt (Recent Filing)
- CHF 636.03M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 0.28
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Sephience Commercial Traction
Sephience is demonstrating meaningful early adoption across U.S. and international markets, supported by sequential revenue growth and a rising active-patient base. Continued penetration of therapy-naive patients, Kuvan switchers and underserved PKU populations could provide a durable commercial growth platform.
Revenue Growth And Breakeven Path
Raised guidance and management’s expected 2026 cash flow breakeven indicate improving operating scale and a clearer path toward internally funded growth. If product expansion continues, stronger cash generation could support pipeline investment while reducing dependence on external financing.
Late-Stage Pipeline Expansion
Adding a BLA-stage Fabry gene therapy gives PTC a potentially commercial-stage asset beyond its existing franchises and broadens its rare-disease platform. The one-time treatment model and planned 2027 launch could create a new growth avenue if regulatory execution remains successful.
Bears Say
Uneven Profitability And Cash Flow
Recent cash generation has not yet proven durable because strong 2025 results were followed by only slightly positive operating cash flow and negative free cash flow on a TTM basis. Continued volatility could limit funding flexibility and make the profitability recovery harder to sustain.
Historical Negative Equity
The history of negative equity signals that PTC has operated with a weak capital structure through several years, even though the latest TTM position has improved. This legacy reduces balance-sheet resilience and leaves less margin for error if operating performance weakens again.
Generic Pressure On Emflaza
Increasing generic competition can structurally erode Emflaza pricing and contribution, reducing the durability of revenue from an established DMD product. The pressure may also shift the portfolio’s dependence toward successful Sephience expansion and new pipeline launches.
PTC Therapeutics News
P91 FAQ
What is PTC Therapeutics’s market cap?
When is PTC Therapeutics’s upcoming earnings report date?
How were PTC Therapeutics’s earnings last quarter?
Is PTC Therapeutics overvalued?
Does PTC Therapeutics pay dividends?
What is PTC Therapeutics’s EPS estimate?
What happened to PTC Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of PTC Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
PTC Therapeutics Stock Smart Score
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Matthew Klein
- Employees
- 991
- Website
- www.ptcbio.com
- Address
- 500 Warren Corporate Center Drive, Warren, NJ, 07059, US
PTC Therapeutics (P91) Earnings & Revenues
P91 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, driven by record product revenue, a more than 100% year-over-year increase in product revenue, raised 2026 guidance, strong Sephience launch momentum, a large remaining PKU opportunity, progress across the pipeline and a strengthened cash position. The main challenges were generic pressure on Emflaza, the lack of expected repeat government orders for Translarna in the fourth quarter, pending international reimbursement decisions, cumulative Sephience discontinuations in the low 20% range and the delayed votoplam FDA meeting. Highlights significantly outweighed lowlights.
View all CH:P91 earnings summaries











